Real-world remibrutinib use for chronic hives in Germany
Part of Immune system & allergy, Skin clinical trials.
This study observes how remibrutinib (a newer medication) works for chronic hives (CSU) when prescribed in routine clinical practice in Germany. Remibrutinib is used when standard allergy medications don't work well enough. The study tracks your symptoms and treatment over 24 months to understand how well it helps real patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of chronic spontaneous urticaria (chronic hives) from your doctor
- Age 18 or older
- Willing and able to keep electronic records (e-diary or app) about your symptoms for 24 months
- Your doctor has decided, independent of this study, to switch you to remibrutinib because your current allergy medication(s) aren't controlling your hives well enough
- Not currently in any other clinical trials or studies, and have not received remibrutinib before
- Able to provide written consent and complete the full 24-month follow-up period
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with chronic hives (CSU) who start taking remibrutinib as part of their normal care. It looks at how well the medicine works in real life over 24 months.
This study observes how well remibrutinib works for people with chronic hives (CSU) in everyday medical practice. It compares three groups based on treatments you have tried, and checks if switching to remibrutinib helps control symptoms.
This study follows people with chronic spontaneous urticaria (long-lasting hives with no clear cause) who are starting a new medicine called remibrutinib or dupilumab. It aims to see how well these treatments work in everyday life.
This program offers remibrutinib, an experimental oral medication, to adults with chronic spontaneous urticaria (long-lasting hives without a known trigger) that hasn't improved with standard antihistamines or omalizumab. It aims to see if this drug can reduce symptoms when other options haven't worked.
This trial tests a treatment plan using remibrutinib (a pill) and omalizumab (a biologic shot) for adults with chronic spontaneous urticaria (chronic hives) that are not well controlled by antihistamines. The goal is to see if this combination can reduce itching and hives better than current options.
This study tests a new medication called HRS-3095 to see if it can help people whose chronic hives (itchy welts) do not get better with standard allergy pills. It aims to reduce itching and wheals and improve quality of life.
Hear when a new Chronic Spontaneous Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.